. 2011 May;4(5):22–26.

Table 2.

Mean reduction (log₁₀ and percent) in total P. acnes and in resistant subpopulations during treatment with adapalene-BPO

	BASELINE VALUES		CHANGE AT WEEK 2			CHANGE AT WEEK 4
	N	MEAN (SD)	N	LOG₁₀ MEAN (SD)	PERCENT MEAN (SD)	N	LOG₁₀ MEAN (SD)	PERCENT MEAN (SD)
Total P. acnes	30	6.7 (0.28)	30	−1.1 (0.81)^*	−80% (21.6)^*	30	−1.6(0.78)^*	−93% (8.1)^*
Erythromycin-resistant P. acnes	30	5.4 (0.85)	30	−1.7(1.02)^*	−89% (20.4)^*	26	−2.2 (0.86)^*	−97% (8.9)^*
Clindamycin-resistant P. acnes	30	5.3 (0.96)	30	−1.7(1.22)^*	−82% (32.1)^*	27	−2.1 (1.15)^*	−92% (19.7)^*
Tetracycline-resistant P. acnes	30	4.2(1.34)	26	−1.3(0.97)^*	−79% (25.7)^*	16	−1.9(0.92)^*	−92% (15.6)^*
Minocycline-resistant P. acnes	30	4.0(1.47)	25	−1.6(1.19)^*	−85% (22.6)^*	13	−2.4(1.29)^*	−97% (3.7)^*
Doxycycline-resistant P. acnes	30	3.8(1.41)	27	−1.1 (1.21)^*	−67% (28.0)^*	22	−1.3(0.75)^*	−88% (14.5)^*

All P<0.001 by t-test comparing change from baseline to zero (if change from baseline was normally distributed) or by Wilcoxon signed rank test comparing change from baseline to zero (if the change from baseline was not normally distributed)